Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
By J. Wood, K. Bonjean, S. Ruetz, A. Bellahcène, L. Devy, J. Foidart, V. Castronovo, Jonathan R. Green. Journal of Pharmacology and Experimental Therapeutics, 2002
894 citations recorded by the source corpus.
Subfields: Oncology, Orthopedics and Sports Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/6f044bd079f8b678940b59f35b2bdae65e106e49
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Rheumatology
Citations in the corpus
- Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws (2006, background): “antiangiogenesis properties (8, 9) and can activate T cells (10, 11).”
- Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. (2006, background): “These include doxycycline [4,5], zolendronate [6], rosiglitazone [7], celecoxcib [8], and low-dose interferon alpha [9,10] Furthermore, certain other anti-cancer drugs that were originally designed to inhibit a growth factor receptor, (i.”
- Opinion: Angiogenesis: an organizing principle for drug discovery? (2007, background): “Zoledronate (Zometa; Novartis) is an amino-bisphosphonate that has been shown to inhibit angiogenesi”
- Gammadelta T cells for immune therapy of patients with lymphoid malignancies. (2003, neutral): “1 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 ( 38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75) 2 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 ( 37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)”
- An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. (2004, methodology): “Seeking to investigate the mechanistic basis for the observed histological responses in the neoplastic lesions, we assessed the frequency of apoptosis and found substantially increased frequencies of apoptosis in both transformed cervical epithelia and ECs, much as we and others have seen in the cou”
- Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. (2008, neutral): “(147, 148) while inducing endothelial cell apoptosis in vivo”
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010, background): “Since only 6 women in the subset with pelvic radiographs had taken BPs, more data are required on the role of cortical thickness in atypical femoral fractures in BP users.”